Stockscreener 앱 받기
78.35
0.54%
0.42
시간 외 거래:
78.35
전일 마감가:
$77.93
열려 있는:
$77.82
하루 거래량:
2.88M
Relative Volume:
0.67
시가총액:
$45.96B
수익:
$5.69B
순이익/손실:
$4.14B
주가수익비율:
11.26
EPS:
6.96
순현금흐름:
$577.90M
1주 성능:
-1.24%
1개월 성능:
+2.57%
6개월 성능:
+11.37%
1년 성능:
+23.80%
1일 변동 폭
$77.41
$78.56
1주일 범위
$77.22
$80.50
52주 변동 폭
$62.88
$83.00
에드워즈라이프사이언시스 Stock (EW) Company Profile
명칭
Edwards Lifesciences Corp
전화
(949) 250-2500
주소
ONE EDWARDS WAY, IRVINE, CA
EW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
78.35 | 46.11B | 5.69B | 4.14B | 577.90M | 6.96 |
|
ABT
Abbott Laboratories
|
134.28 | 227.88B | 43.11B | 13.98B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.14 | 152.55B | 18.49B | 2.51B | 3.23B | 1.68 |
|
SYK
Stryker Corp
|
377.58 | 143.34B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.88 | 114.49B | 33.54B | 4.66B | 5.19B | 3.62 |
에드워즈라이프사이언시스 Stock (EW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-04-24 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | 업그레이드 | Stifel | Hold → Buy |
| 2025-01-16 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2024-09-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-07-31 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-07-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-25 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-07-25 | 다운그레이드 | Truist | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-05-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-03-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-02-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-28 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Overweight |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-03-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | 다운그레이드 | Bernstein | Outperform → Underperform |
| 2023-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 개시 | Mizuho | Buy |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-29 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 개시 | Truist | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-27 | 재확인 | Citigroup | Buy |
| 2022-01-27 | 재확인 | Evercore ISI | Outperform |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | Stifel | Buy |
| 2022-01-27 | 재확인 | UBS | Neutral |
| 2021-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-12-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-30 | 재확인 | Deutsche Bank | Hold |
| 2021-07-30 | 재확인 | Jefferies | Buy |
| 2021-07-30 | 재확인 | Morgan Stanley | Overweight |
| 2021-07-30 | 재확인 | Oppenheimer | Outperform |
| 2021-07-30 | 재확인 | Stifel | Buy |
| 2021-07-30 | 재확인 | UBS | Neutral |
| 2021-07-30 | 재확인 | Wells Fargo | Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-04-05 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-11 | 재확인 | Canaccord Genuity | Buy |
| 2020-09-11 | 개시 | Wolfe Research | Underperform |
| 2020-04-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Outperform |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 재확인 | Canaccord Genuity | Buy |
| 2019-09-23 | 개시 | Piper Jaffray | Overweight |
| 2019-07-24 | 재확인 | BofA/Merrill | Buy |
| 2019-03-18 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-18 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Hold |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-16 | 개시 | Barclays | Underweight |
| 2018-10-02 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
모두보기
에드워즈라이프사이언시스 주식(EW)의 최신 뉴스
FTC Sues to Block Edwards LifeSciences Medical Device Deal - MSN
FTC Sounds Alarm On Edwards’ Heart Device, M&A AttemptEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Lifesciences Leads Heart Device Market With Value Upside - Finimize
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve - MSN
Edwards Lifesciences’ ALT-FLOW II Trial: A Key Update for Heart Failure Treatment - TipRanks
FTC moves to block Edwards’ acquisition of JenaValve Technology - Medical Buyer
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve - WKZO
FTC sues to block Edwards Lifesciences' $945M JenaValve deal - Daily Journal
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
FTC sues to block Edwards Lifesciences purchase of JenaValve - MSN
FTC seeks to block Edwards Lifesciences' acquisition of JenaValve | Business Information & News | FE - Westlaw Today
Hulu-Disney Plus Merger Moves Forward - PYMNTS.com
FTC Files Lawsuit to Block Edwards Lifesciences’ Purchase of JenaValve Technology - The Wall Street Journal
Edwards Lifesciences' deal with JenaValve would limit device access, US FTC says - MLex
FTC moves to block Edwards Lifesciences’ JenaValve acquisition - MassDevice
JenaValve Responds to FTC’s Action Against Proposed Edwards Lifesciences Acquisition - The Manila Times
Jenavalve disagrees with FTC's decision against proposed Edwards Lifesciences deal - MarketScreener
JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition - Benzinga
FTC seeks to block Edwards Lifesciences’ acquisition of JenaValve By Reuters - Investing.com
Edwards Lifesciences Fights FTC Block of JenaValve Deal as EPS Guidance Jumps to $2.55 - Stock Titan
Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027 - Benzinga
Edwards Lifesciences Corporation's (NYSE:EW) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance
How volatile is Edwards Lifesciences Corporation stock compared to the marketFree Stock Selection - Jammu Links News
Is Edwards Lifesciences Corporation a growth stock or a value stockHigh-octane investment gains - Jammu Links News
What catalysts could drive Edwards Lifesciences Corporation stock higher in 2025Build wealth with professional market analysis - Jammu Links News
Is it the right time to buy Edwards Lifesciences Corporation stockSuperior portfolio returns - Jammu Links News
How many analysts rate Edwards Lifesciences Corporation as a “Buy”Strongest growth potential - Jammu Links News
What are the technical indicators suggesting about Edwards Lifesciences CorporationMarket-crushing stock picks - Jammu Links News
Should I hold or sell Edwards Lifesciences Corporation stock in 2025Real Time Alerts For Fast Growth - Jammu Links News
Edwards Lifesciences’ SAPIEN 3 Valve Study: A Real-World Evaluation - TipRanks
Edwards Lifesciences’ PASCAL System: A Promising Update in Tricuspid Valve Repair - TipRanks
Agree To Purchase Edwards Lifesciences At $65, Earn 5.2% Using Options - Nasdaq
How Edwards Lifesciences Corporation stock reacts to Fed policy changesAI Powered High Return Stock Calls Dominate Watchlists - beatles.ru
Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here’s Why - Yahoo Finance
Edwards Lifesciences’ SAPIEN 3 Study: A Market Game-Changer? - TipRanks
A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $84 to $100 - 富途牛牛
Edwards Lifesciences Stock (EW) Opinions on Q2 Earnings Beat - Quiver Quantitative
Edwards Lifesciences’ Pivotal Trial: A Game-Changer for Tricuspid Valve Repair? - TipRanks
Edwards Lifesciences Corporation (NYSE:EW) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts upgrade Edwards as TAVR segment improves - MassDevice
BTIG upgrades Edwards Lifesciences stock to Buy on TAVR segment stability - Investing.com
Edwards Lifesciences prevails in heart valve dispute at the UPC - JUVE Patent
Edwards Lifesciences Insider Makes a Major Stock Move! - TipRanks
Edwards Lifesciences Reports Strong Growth and Raises Guidance - TipRanks
Edwards Lifesciences debuts heart valve failure PSA as Rams training camp begins - Medical Marketing and Media
Edwards Lifesciences stock price target raised to $85 by Bernstein - Investing.com
Edwards Lifesciences stock price target raised to $85 by UBS on strong TAVR sales - Investing.com
Edwards Lifesciences’ SWOT analysis: strong TAVR growth boosts stock outlook - Investing.com
When is Edwards Lifesciences Corporation stock expected to show significant growthExceptional return forecasts - jammulinksnews.com
에드워즈라이프사이언시스 (EW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
자본화:
|
볼륨(24시간):